Viatris Financials

Viatris Stock Summary

Viatris competes with Hawkins, Boston Omaha, Alto Ingredients, Luxfer Holdings, and Ecolab. Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter pharmaceutical products in North America, Europe, and internationally. The company was founded in 1961 and is based in Hatfield, the United Kingdom. Mylan NV operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 35000 people.

Viatris Key Financial Ratios

Generally speaking, Viatris' financial ratios allow both analysts and investors to convert raw data from Viatris' financial statements into concise, actionable information that can be used to evaluate the performance of Viatris over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Viatris reports annually and quarterly.

Viatris Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Viatris's current stock value. Our valuation model uses many indicators to compare Viatris value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Viatris competition to find correlations between indicators driving Viatris's intrinsic value. More Info.Viatris is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies reporting about  1.64  of Return On Asset per Return On Equity. Comparative valuation analysis is a catch-all model that can be used if you cannot value Viatris by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Viatris' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Viatris' earnings, one of the primary drivers of an investment's value.

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

If you are still planning to invest in Viatris check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Viatris' history and understand the potential risks before investing.